Geovax Labs Inc (GOVX)
2.58
-0.12
(-4.44%)
USD |
NASDAQ |
Nov 14, 16:00
2.57
-0.01
(-0.39%)
After-Hours: 17:59
Geovax Labs Research and Development Expense (Quarterly): 4.277M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.277M |
| March 31, 2024 | 4.426M |
| December 31, 2023 | 6.234M |
| September 30, 2023 | 6.948M |
| June 30, 2023 | 4.720M |
| March 31, 2023 | 2.819M |
| December 31, 2022 | 3.765M |
| September 30, 2022 | 2.721M |
| June 30, 2022 | 1.307M |
| March 31, 2022 | 1.330M |
| December 31, 2021 | 12.89M |
| September 30, 2021 | 1.224M |
| June 30, 2021 | 0.8328M |
| March 31, 2021 | 0.6028M |
| December 31, 2020 | 0.7573M |
| September 30, 2020 | 0.4168M |
| June 30, 2020 | 0.4614M |
| March 31, 2020 | 0.8089M |
| December 31, 2019 | 0.4361M |
| September 30, 2019 | 0.4677M |
| June 30, 2019 | 0.4512M |
| March 31, 2019 | 0.5557M |
| December 31, 2018 | 0.4618M |
| September 30, 2018 | 0.5577M |
| June 30, 2018 | 0.3722M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.487M |
| December 31, 2017 | 0.4493M |
| September 30, 2017 | 0.4982M |
| June 30, 2017 | 0.5181M |
| March 31, 2017 | 0.5518M |
| December 31, 2016 | 0.4513M |
| September 30, 2016 | 0.6839M |
| June 30, 2016 | 0.3976M |
| March 31, 2016 | 0.438M |
| December 31, 2015 | 0.5263M |
| September 30, 2015 | 0.3785M |
| June 30, 2015 | 0.3847M |
| March 31, 2015 | 0.4036M |
| December 31, 2014 | 0.4928M |
| September 30, 2014 | 0.4181M |
| June 30, 2014 | 0.5162M |
| March 31, 2014 | 0.4029M |
| December 31, 2013 | 0.6006M |
| September 30, 2013 | 0.8791M |
| June 30, 2013 | 0.5532M |
| March 31, 2013 | 0.882M |
| December 31, 2012 | 0.6571M |
| September 30, 2012 | 0.6017M |
| June 30, 2012 | 0.7124M |
| March 31, 2012 | 1.072M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.4168M
Minimum
Sep 2020
12.89M
Maximum
Dec 2021
2.999M
Average
1.330M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Emergent BioSolutions Inc | 32.70M |
| Tonix Pharmaceuticals Holding Corp | 9.698M |
| Abbott Laboratories | 713.00M |
| SIGA Technologies Inc | -- |
| Chimerix Inc | 18.43M |